Previous 10 | Next 10 |
2024-01-06 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-21 16:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-10 09:28:29 ET More on AN2 Therapeutics AN2 Therapeutics director and 10% owner disposes stake in the company AN2 Therapeutics prices $70.0 million stock offering Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2...
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease On track to announce Phase 2 clinical data summer 2024 Cash and investments of $150.2 million at September 30, 2023; c...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
AN2 Therapeutics Inc. (ANTX) is expected to report $-0.63 for Q3 2023
License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in partnership with University of Georgia Chagas expert using non dilutive f...
Enrollment Ongoing in Phase 3 Part of 2/3 Pivotal Trial of Epetraborole in Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
2023-10-04 11:58:18 ET More on AN2 Therapeutics AN2 Therapeutics prices $70.0 million stock offering Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics Financial information for AN2 Therapeutics For f...
Grant from Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant...
News, Short Squeeze, Breakout and More Instantly...
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...